Issues related to prior authorization.
2026 · 3rd Quarter (July 1 - Sep 30)
THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Filed by THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES).
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2026
- Income
- Not reported
- Expenses
- $2,650,000.00
- Filing UUID
- 7554bc36-d3b5-4100-be6f-9da69f4336f1
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Issues related to PBM and drug pricing reform, health care transparency and affordability. P.L. 119-75 Consolidated Appropriations Act, 2026. Issues related to the specialty drug market.
Issues related to Tricare pharmacy issues.
Issues related to health plan and PBM transparency, employer sponsored health insurance. Issues related to the No Surprises Act.
Issues related to competition in the health care marketplace.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.